enGene Holdings (enGene Holdings) 6-Month Price Index : 1.69 (As of May. 23, 2024)

View and export this data going back to 2023. Start your Free Trial

What is enGene Holdings 6-Month Price Index?

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2024-05-23), enGene Holdings's 6-Month Price Index is 1.69.

Competitive Comparison of enGene Holdings's 6-Month Price Index

For the Biotechnology subindustry, enGene Holdings's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

enGene Holdings (NAS:ENGN) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index

Current Share Price

Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

enGene Holdings (NAS:ENGN) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

enGene Holdings 6-Month Price Index Related Terms

Thank you for viewing the detailed overview of enGene Holdings's 6-Month Price Index provided by GuruFocus.com. Please click on the following links to see related term pages.

enGene Holdings (enGene Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » enGene Holdings Inc (NAS:ENGN) » Definitions » 6-Month Price Index

Comparable Companies

Traded in Other Exchanges

N/A

Address

7171 Rue Frederick Banting, Saint-Laurent, QC, CAN, H4S 1Z9

Website

enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Executives

Richard M Glickman	director	C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jason David Hanson	director, officer: Chief Executive Officer	8125 NORTH HAYDEN ROAD, SCOTTSDALE AZ 85258-2463
Lumira Capital Investment Management Inc.	10 percent owner	141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Richard Paul Bryce	officer: Chief Medical Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Fonds De Solidarite Des Travailleurs Du Quebec	10 percent owner	545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4
Gerald A Brunk	director	C/O MDS CAPITAL, 245 FIRST ST., STE 1800, CAMBRIDGE MA 02142
Jasper Bos	director	BOUNDARY HALL, PO BOX 1093, CRICKET SQUARE, GRAND CAYMAN E9 KY1-1102
Grassin Alexandre Jean-rene Erwan	officer: Int. Chief Financial Officer	7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Anthony Tzeyew Cheung	officer: Chief Technology Officer	7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Alexander Julian Nichols	officer: Pres. & Chief Operating Ofc.	7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
James Crowley Sullivan	officer: Chief Scientific Officer	7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Forbion Growth Sponsor Feac I B.v.	10 percent owner	GOOIMEER 2 35,, NAARDEN P7 1411DC
Forbion Growth Opportunities Fund I Cooperatief U.a.	10 percent owner	GOOIMEER 235, 1411 DC, NAARDEN P7 00000
Forbion Growth Management B.v.	10 percent owner	C/O FORBION EUROPEAN ACQUISITION CORP., 4001 KENNETT PIKE, SUITE 302, WILMINGTON DE 19807

enGene Holdings (enGene Holdings) Headlines

From GuruFocus

enGene Announces Expanded $50 Million Debt Facility with Hercules Capital

By PRNewswire • 12-22-2023

enGene Appoints Ryan Daws as Chief Financial Officer

By PRNewswire • 11-29-2023

enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors

By PRNewswire • 12-19-2023